PT  - JOURNAL ARTICLE
AU  - Véronique D’Hondt
AU  - Frédéric Goffin
AU  - Lise Roca
AU  - Damien Dresse
AU  - Chantal Leroy
AU  - Joseph Kerger
AU  - Lionel Cordier
AU  - Hélène de Forges
AU  - Isabelle Veys
AU  - Gabriel Liberale
TI  - Interval Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First-Line Treatment for Advanced Ovarian Carcinoma: A Feasibility Study
AID  - 10.1097/IGC.0000000000000696
DP  - 2016 Jun 01
TA  - International Journal of Gynecologic Cancer
PG  - 912--917
VI  - 26
IP  - 5
4099  - http://ijgc.bmj.com/content/26/5/912.short
4100  - http://ijgc.bmj.com/content/26/5/912.full
SO  - Int J Gynecol Cancer2016 Jun 01; 26
AB  - Objectives We conducted a phase 2 trial to assess the feasibility of interval cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in patients with stage III and IV pleural ovarian carcinoma in first-line treatment with no macroscopic residual disease after surgery.Methods Patients could be treated either with primary CS with HIPEC followed by 6 conventional cycles of chemotherapy or with 3 or 4 cycles of neoadjuvant chemotherapy before CS with HIPEC and 3 postoperative chemotherapy cycles. Hyperthermic intraperitoneal chemotherapy was performed with cisplatin (50 mg/m2) for 60 minutes, only in case of complete cytoreduction.Results Nineteen patients were included in the study, and they all underwent neoadjuvant chemotherapy before CS. Sixteen patients underwent complete CS with HIPEC. There was no mortality, and morbidity of CS with HIPEC was acceptable. The HIPEC procedure did not prevent the administration of the standard first-line treatment. In the 16 patients who underwent CS with HIPEC, the outcomes were very good.Conclusion Our study shows an acceptable toxicity of adding HIPEC to the standard first-line treatment in patients with stage III ovarian carcinoma treated with interval CS. Further studies are needed to confirm the role of HIPEC in the treatment of ovarian carcinoma.